biochimica clinica

it_IT Italian
it_IT Italian en_US English

CASI CLINICI – Case Reports

Volume:

Biochimica Clinica 2021; 45(3) s107-s110

Pubblicato on-line:

Luglio 23, 2021

DOI:

10.19186/BC_2021.056

Scarica in PDF:

Remissione di iperparatiroidismo secondario dopo nefrectomia in un paziente emodializzato: ruolo di Etelcalcetide
Secondary hyperparathyroidism remission after nephrectomy in a dialysis patient: role of Etelcalcetide

AUTORI

Stefano Aterini1, Francesca Calderini2, Marco Gallo1, Sandro Bandini1, Santi Nigrelli1, Daniela Sacchi1, Francesco Guzzi1, Lorenzo Aterini1, Fiamma Balboni2
1UO Nefrologia e Dialisi - Istituto Fiorentino di Cura e Assistenza - IFCA Firenze
2Laboratorio Analisi - Istituto Fiorentino di Cura e Assistenza - IFCA Firenze

ABSTRACT

Secondary hyperparathyroidism remission after nephrectomy in a dialysis patient: role of Etelcalcetide

Secondary hyperparathyroidism (HPT) is a common issue in dialysis patients; it contributes significantly to their morbidity and mortality. Here we describe the case of a hemodialysis patient with severe secondary HPT, treated with Etelcalcetide, the new intravenous calcimimetic agent, employed after a nephrectomy due to a renal neoplasm to reduce successfully the serum levels of parathyroid hormone (PTH) and bone specific alkaline phosphatase (BAP). No significant change in serum calcium was recorded during treatment, while the already high serum phosphorus concentrations further increased after surgery. By maintaining the calcium mimetic therapy, even if at lower doses, the concentrations of PTH and BAP remained constant over the time.

BIBLIOGRAFIA